Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Type 2 diabetes across 7MM faces growing comorbidity burden amid rising obesity and aging, reveals GlobalData

Type 2 diabetes is carrying a growing burden of comorbidities across the seven major markets (7MM*), with hypertension emerging as the most prevalent diagnosed condition among patients with the disease. Higher BMI, sedentary lifestyles, poor diets, and aging populations are intensifying this burden, highlighting the need for more comprehensive disease management and prevention strategies, according […]
Read more

Long-acting therapies continue to gain momentum in HIV, says GlobalData

The next phase of competition in the HIV market will be defined not only by achieving viral suppression, but by improving treatment adherence, reducing medication burden and delivering more convenient treatment options, with long-acting therapies at the forefront, according to GlobalData, a leading intelligence and productivity platform. GlobalData forecasts that the HIV market across the […]
Read more

ICON keeps lead as most active CRO in Q2 2026, reveals GlobalData

ICON maintains its place as the most active contract research organization (CRO) for Q2 2026, and France knocks Russia from its spot with the most clinical trials initiated in Europe, according to a report by GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report “Q2 2026 CRO Activity and Intel Report,” reveals pain was the most […]
Read more

European drug manufacturers under threat from proposed US supply chain bill, says GlobalData

US efforts to scrutinize overseas pharmaceutical manufacturing could expose Europe’s dominant role in supplying FDA-approved innovator and biosimilar drugs, reshaping global biopharma supply chains. Analysis indicates Germany faces the greatest commercial risk as Washington pursues onshoring policies that may trigger tariff and non-tariff measures, creating fresh investment, manufacturing, and market access challenges for pharmaceutical companies […]
Read more

Cell and gene therapy manufacturers turn to specialist automation partners, says GlobalData

Cell and gene therapy manufacturers are partnering with specialist technology companies to address the challenges associated with scaling complex therapies. Recent collaborations between developers, contract development and manufacturing organizations (CDMOs), and automation companies demonstrate how robotics, digital systems, and advanced manufacturing platforms are being integrated into production workflows to support more scalable and efficient manufacturing, […]
Read more

FDA regenerative medicine approvals gain momentum, reveals GlobalData

Following several years of limited activity, FDA approvals for regenerative medicines have accelerated, culminating in a record eight approvals in 2024. Recent findings also highlight a surge in regenerative medicine advanced therapy (RMAT) designations, which, together with a robust late-stage pipeline, suggests that FDA approval activity for regenerative medicine products is likely to remain elevated […]
Read more

Niktimvo approval in Australia reinforces momentum for macrophage-targeted cGVHD therapies, says GlobalData

Australia’s Therapeutic Goods Administration (TGA) approved Niktimvo (axatilimab) for chronic graft-versus-host disease (cGVHD) in May 2026, making Australia the first market outside the US to authorize the therapy. The decision strengthens the role of macrophage-targeted treatments for heavily pretreated patients, while highlighting reimbursement, real-world adoption, and earlier-line evidence as key factors shaping its long-term clinical […]
Read more

Dimerix’s DMX-652 acquisition to bolster kidney disease therapy development, says GlobalData

Dimerix recently announced the acquisition of DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury (AKI) program with a differentiated mechanism. The acquisition expands Dimerix beyond its late-stage focal segmental glomerulosclerosis (FSGS) asset. The company already has a late-stage rare kidney disease asset in FSGS, so adding DMX-652 creates a continuum from acute […]
Read more

MASH market growth in India hinges on awareness-led strategies, says GlobalData

Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) market in India is entering a new phase, with awareness-driven strategies expected to play a pivotal role in improving diagnosis, treatment access, and patient outcomes. The expanded approval of semaglutide for adults with MASH and fibrosis stages F2–F3 marks a significant development, while rising diagnosed prevalence and growing awareness initiatives […]
Read more

China’s biotech rise to face challenges from US policy responses, says GlobalData

China is emerging as a global biotechnology innovation hub, but its growing influence is facing political and regulatory scrutiny from the US. The US policy response reflects concerns around its competitiveness and technological leadership, rather than the country’s scientific capability alone, says GlobalData, a leading intelligence and productivity platform. China’s scientific progress was on display […]
Read more

Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI manufacturing, says GlobalData

Known for their low-dose therapeutic efficacy and high target affinity, high-potency active pharmaceutical ingredients (HPAPIs) are in high demand by biopharma companies, which often outsource their production. Approximately 41% of innovator and biosimilar HPAPIs come from contract development and manufacturing organizations (CDMOs). With strategic acquisitions and expansions of HPAPI facilities reshaping the HPAPI outsourcing market, […]
Read more

EU approval of Arrowhead’s Redemplo to expand FCS treatment options, says GlobalData

Arrowhead Pharmaceuticals has recently announced that the European Commission has granted marketing authorization for Redemplo (plozasiran), an innovative apolipoprotein C III (apoC-III) inhibitor that is already approved in the US for the treatment of adults with familial chylomicronemia syndrome (FCS). The approval was supported by Phase III data demonstrating substantial reductions in triglyceride levels and […]
Read more

Diagnosed incident cases of hepatocellular carcinoma across 8MM to reach 370,000 in 2034, forecasts GlobalData

The diagnosed incident cases of hepatocellular carcinoma (HCC) in the eight major markets (8MM*) are projected to increase at an annual growth rate (AGR) of 2.06%, from over 306,000 in 2024 to approximately 370,000 by 2034, according to  GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast”, […]
Read more

Diagnosed prevalent cases of overweight and obesity across 7MM to reach over 260 million in 2035, forecasts GlobalData

The diagnosed prevalent cases of overweight and obesity combined in the seven major markets (7MM*) are set to increase at an annual growth rate (AGR) of 0.61%, from over 245 million in 2025 to 260 million in 2035, forecasts GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Overweight and Obesity: Epidemiology Report and […]
Read more

FDA-awarded RMAT designations continue to surge in 2025, reveals GlobalData

Since the FDA first awarded a regenerative medicine advanced therapeutic (RMAT) designation in 2017, activity in this space remained relatively modest until 2023. However, the number of RMAT designations increased sharply in 2024, reaching a record of 48 RMAT designations in 2025, reflecting the expanding regenerative medicine landscape and suggesting that a larger number of […]
Read more
1 2 3 … 109